Drug/drug delivery systems for the prevention and treatment of vascular disease
DCFirst Claim
Patent Images
1. A drug delivery device comprising:
- an intraluminal stent;
a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and
from about 64 μ
g to about 197 μ
g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.5 mm, as measured by quantitative coronary angiography.
2 Assignments
Litigations
0 Petitions
Reexamination
Accused Products
Abstract
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.
472 Citations
25 Claims
-
1. A drug delivery device comprising:
- an intraluminal stent;
a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and
from about 64 μ
g to about 197 μ
g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.5 mm, as measured by quantitative coronary angiography. - View Dependent Claims (2, 3, 4, 17, 18, 19, 20, 21)
- an intraluminal stent;
-
5. A drug delivery device comprising:
- an intraluminal stent;
a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and
from about 64 μ
g to about 197 μ
g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. - View Dependent Claims (6, 7, 8)
- an intraluminal stent;
-
9. A method of inhibiting neointimal proliferation in a human coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising:
- an intraluminal stent;
a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and
from about 64 μ
g to about 197 μ
g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides an in-stent late loss in diameter at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. - View Dependent Claims (10, 11, 12, 22, 23, 24, 25)
- an intraluminal stent;
-
13. A method of inhibiting neointimal proliferation in a coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising:
- an intraluminal stent;
a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and
from about 64 μ
g to about 197 μ
g of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. - View Dependent Claims (14, 15, 16)
- an intraluminal stent;
Specification